About PhRMA
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are laser focused on developing innovative medicines that transform lives and create a healthier world. Together, we are fighting for solutions to ensure patients can access and afford medicines that prevent, treat and cure disease. Over the last decade, PhRMA member companies have invested more than $850 billion in the search for new treatments and cures, and they support nearly five million jobs in the United States.
Connect with PhRMA
For information on how innovative medicines save lives, please visit:
www.PhRMA.org
www.VotersforCures.org
www.AmericasMedicines.com
www.Facebook.com/PhRMA
www.X.com/PhRMA
World Trade Organization (WTO) members are considering waiving commitments to honor certain intellectual property (IP) rights on COVID-19 treatments, following a harmful and unnecessary decision to do the same for COVID-19 vaccines. This is referred to as the TRIPS waiver. Any expansion of the TRIPS waiver would: 1.) Compromise global public health and harm patients; 2.) Cede American IP to foreign countries, sending research and manufacturing jobs overseas; 3.) Undercut American innovation and jeopardize our ability to respond to future pandemics; and 4.) Harm global collaboration and undermine U.S. leadership in the biopharmaceutical sector. Biopharmaceutical manufacturers are already sharing their IP and remain committed to providing timely global access to safe and effective COVID-19 vaccines and treatments.
The Danger of Waiving TRIPS Intellectual Property Rights at the WTO image
Fact Sheet
Medicine Safety
The Danger of Waiving TRIPS Intellectual Property Rights at the WTO
The Danger of Waiving TRIPS Intellectual Property Rights at the WTO image